Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents

Journal of Infection and Public Health

Volumn 7, Issue 2, 2014, Pages 145-152

  Chang, Shiow Huey ^a   Eitzman, Sarah R ^b,c   Nahid, Payam ^d   Finelli, Maria Lourdes U ^b  

^a Public Health Department   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse effects; Compliance; Hepatitis; Mycobacterium; Treatment

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS; HUMAN; INFANT; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; NEWBORN; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

ADVERSE EFFECTS; COMPLIANCE; HEPATITIS; MYCOBACTERIUM; TREATMENT;

ADOLESCENT; AGE FACTORS; ANTITUBERCULAR AGENTS; CALIFORNIA; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHNIC GROUPS; FEMALE; HUMANS; INFANT; ISONIAZID; LATENT TUBERCULOSIS; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES;

EID: 84896083429     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2013.11.001     Document Type: Article

References (23)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000, 161:S221-S247.
2. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics 2004, 114(Suppl. 4):1175-1201. Pediatric Tuberculosis Collaborative Group. 10.1542/peds.2004-0809.
3. Cruz A.T., Starke J.R. Increasing adherence for latent tuberculosis infection therapy with health department-administered therapy. Pediatr Infect Dis J 2012, 31:193-195.
4. Li J., Munsiff S.S., Tarantino T., Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis 2010, 14:e292-e297.
5. Powell D.A., Perkins L., Wang S.H., Hunt G., Ryan-Wenger N. Completion of therapy for latent tuberculosis in children of different nationalities. Pediatr Infect Dis J 2008, 27:272-274.
6. Cass A.D., Talavera G.A., Gresham L.S., Moser K.S., Joy W. Structured behavioral intervention to increase children's adherence to treatment for latent tuberculosis infection. Int J Tuberc Lung Dis 2005, 9:415-420.
7. LoBue P.A., Moser K.S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003, 168:443-447.
8. Parsyan A.E., Saukkonen J., Barry M.A., Sharnprapai S., Horsburgh C.R. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007, 54:262-266.
9. Kwara A., Herold J.S., Machan J.T., Carter E.J. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 2008, 133:862-868.
10. Machado A., Finkmoore B., Emodi K., Takenami I., Barbosa T., Tavares M., et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador. Braz Int J Tuberc Lung Dis 2009, 13:719-725.
11. Berg J., Blumberg E.J., Sipan C.L., Friedman L.S., Kelley N.J., Vera A.Y., et al. Somatic complaints and isoniazid (INH) side effects in Latino adolescents with latent tuberculosis infection (LTBI). Patient Educ Couns 2004, 52:31-39.
12. Shukla S.J., Warren D.K., Woeltje K.F., Gruber C.A., Fraser V.J. Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Chest 2002, 122:1609-1614.
13. Minodier P., Lamarre V., Carle M.E., Blais D., Ovetchkine P., Tapiero B. Evaluation of a school-based program for diagnosis and treatment of latent tuberculosis infection in immigrant children. J Infect Public Health 2010, 3:67-75.
14. Ito K.L. Health culture and the clinical encounter: Vietnamese refugees' responses to preventive drug treatment of inactive tuberculosis. Med Anthropol Q 1999, 13:338-364.
15. Chernick M.R. Bootstrap methods: a guide for practitioners and researchers 2008, John Wiley & Sons Inc., Hoboken, NJ. 2nd ed.
16. Hovell M., Blumberg E., Gil-Trejo L., Vera A., Kelley N., Sipan C., et al. Predictors of adherence to treatment for latent tuberculosis infection in high-risk Latino adolescents: a behavioral epidemiological analysis. Soc Sci Med 2003, 56:1789-1796.
17. Young J., Edick T., Klee D., O'Connor M.E. Successful treatment of pediatric latent tuberculosis infection in a community health center clinic. Pediatr Infect Dis J 2012, 31:e147-e151.
18. Horsburgh C.R., Goldberg S., Bethel J., Chen S., Colson P.W., Hirsch-Moverman Y., et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010, 137:401-409.
19. Shieh F.K., Snyder G., Horsburgh C.R., Bernardo J., Murphy C., Saukkonen J.J. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 2006, 174:717-721.
20. Eidlitz-Markus T., Zeharia A., Baum G., Mimouni M., Amir J. Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection. Chest 2003, 123:736-739.
21. Meissner P.E., Musoke P., Okwera A., Bunn J.E., Coulter J.B. The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda. Int J Tuberc Lung Dis 2002, 6:903-908.
22. Berkovitch M., Papadouris D., Shaw D., Onuaha N., Dias C., Olivieri N.F. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. Br J Clin Pharmacol 1998, 45:605-607.
23. California Department of Public Health Report on tuberculosis in California 2011, Available at: http://www.cdph.ca.gov/data/statistics/Documents/TBCB_Report_2011.pdf [accessed 26.04.13].